Related Experiment Videos
[Hematological recovery after peripheral blood stem cell transplantation followed by recombinant granulocyte
H Fujii1, H Nakagawa, Y Sonoda
1Third Department of Internal Medicine, Kyoto First Red Cross Hospital.
The hematological recovery of 11 patients who received autologous peripheral blood stem cell transplantation (PBSCT) followed by recombinant granulocyte colony-stimulating factor (rG-CSF) was studied. After high-dose cytarabine therapy or high-dose etoposide therapy followed by rG-CSF, the peripheral blood stem cells were collected using CS-3000 during bone marrow recovery and subsequently cryopreserved in 8 patients with malignant lymphoma, 2 with multiple myeloma and 1 with ALL. The infused dose of CFU-GM following myeloablative chemotherapy ranged from 1.9 to 18.1 x 10(5)/kg BW. Nine patients received more than 5 x 10(5) CFU-GM/kg BW. The median time to reach 1,000 WBC/microliter, 500 neutrophils/microliter, 5 x 10(4) platelets/microliter and 1% reticulocytes was 9 (range; 8-12), 9 (range; 8-12), 16 (range; 8-27) and 15 (range; 9-38) days, respectively. A negative correlation was found between the logarithm of CFU-GM/kg BW numbers infused and the time post-transplant to reach 500 neutrophils/microliter (r = -0.82, P < 0.005), 5 x 10(4) platelets/microliter (r = -0.48) and 1% reticulocytes (r = -0.57, p < 0.05). Transient decrease in the neutrophil (n = 3) or platelet counts (n = 9) was observed 4 to 8 weeks after transplantation, but the recovery of hematopoiesis became stable thereafter. We concluded that with combined use of rG-CSF, the minimal CFU-GM dose required for safe PBSCT is 2 x 10(5)/kg BW.
The hematological recovery of 11 patients who received autologous peripheral blood stem cell transplantation (PBSCT) followed by recombinant granulocyte colony-stimulating factor (rG-CSF) was studied. After high-dose cytarabine therapy or high-dose etoposide therapy followed by rG-CSF, the peripheral blood stem cells were collected using CS-3000 during bone marrow recovery and subsequently cryopreserved in 8 patients with malignant lymphoma, 2 with multiple myeloma and 1 with ALL. The infused dose of CFU-GM following myeloablative chemotherapy ranged from 1.9 to 18.1 x 10(5)/kg BW. Nine patients received more than 5 x 10(5) CFU-GM/kg BW. The median time to reach 1,000 WBC/microliter, 500 neutrophils/microliter, 5 x 10(4) platelets/microliter and 1% reticulocytes was 9 (range; 8-12), 9 (range; 8-12), 16 (range; 8-27) and 15 (range; 9-38) days, respectively. A negative correlation was found between the logarithm of CFU-GM/kg BW numbers infused and the time post-transplant to reach 500 neutrophils/microliter (r = -0.82, P < 0.005), 5 x 10(4) platelets/microliter (r = -0.48) and 1% reticulocytes (r = -0.57, p < 0.05). Transient decrease in the neutrophil (n = 3) or platelet counts (n = 9) was observed 4 to 8 weeks after transplantation, but the recovery of hematopoiesis became stable thereafter. We concluded that with combined use of rG-CSF, the minimal CFU-GM dose required for safe PBSCT is 2 x 10(5)/kg BW.